Hematology | Clinical

Moving Forward in the Management of Acute GvHD

December 23, 2020

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

FDA Biologics License Application for JZP-458 Initiated for 2 Leukemia Indications

December 21, 2020

The submission of a Biologics License Application has been initiated seeking approval of JZP-458 as a part of a multi-agent chemotherapy regimen as treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to E. coli-derived asparaginases.

Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

December 15, 2020

Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.

Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy

December 09, 2020

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.